

Review

Open Access

Biological versus chronological ovarian age: implications for assisted reproductive technology

Carlo Alviggi*¹, Peter Humaidan², Colin M Howles³, Donald Tredway⁴ and Stephen G Hillier⁵

Address: ¹Dipartimento di Scienze Ostetriche e Ginecologiche - Medicina della Riproduzione, Università degli Studi di Napoli Federico II, via S. Pansini 5, 80131 Naples, Italy, ²The Fertility Clinic, Skive Regional Hospital, Skive, Denmark, ³Merck Serono S.A. - Geneva (an affiliate of Merck KGaA, Darmstadt, Germany), Geneva, Switzerland, ⁴Endocrinology and Reproductive Health GCDU, EMD Serono, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany), Rockland, MA, USA and ⁵University of Edinburgh, Centre for Reproductive Biology, Edinburgh, UK

Email: Carlo Alviggi* - alviggi@unina.it; Peter Humaidan - peter.humaidan@sygehusviborg.dk; Colin M Howles - colin.howles@merckserono.net; Donald Tredway - donald.tredway@emdserono.com; Stephen G Hillier - Steve.Hillier@ed.ac.uk

* Corresponding author

Published: 22 September 2009

Received: 6 July 2009

Reproductive Biology and Endocrinology 2009, **7**:101 doi:10.1186/1477-7827-7-101

Accepted: 22 September 2009

This article is available from: <http://www.rbej.com/content/7/1/101>

© 2009 Alviggi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Women have been able to delay childbearing since effective contraception became available in the 1960s. However, fertility decreases with increasing maternal age. A slow but steady decrease in fertility is observed in women aged between 30 and 35 years, which is followed by an accelerated decline among women aged over 35 years. A combination of delayed childbearing and reduced fecundity with increasing age has resulted in an increased number and proportion of women of greater than or equal to 35 years of age seeking assisted reproductive technology (ART) treatment.

Methods: Literature searches supplemented with the authors' knowledge.

Results: Despite major advances in medical technology, there is currently no ART treatment strategy that can fully compensate for the natural decline in fertility with increasing female age. Although chronological age is the most important predictor of ovarian response to follicle-stimulating hormone, the rate of reproductive ageing and ovarian sensitivity to gonadotrophins varies considerably among individuals. Both environmental and genetic factors contribute to depletion of the ovarian oocyte pool and reduction in oocyte quality. Thus, biological and chronological ovarian age are not always equivalent. Furthermore, biological age is more important than chronological age in predicting the outcome of ART. As older patients present increasingly for ART treatment, it will become more important to critically assess prognosis, counsel appropriately and optimize treatment strategies. Several genetic markers and biomarkers (such as anti-Müllerian hormone and the antral follicle count) are emerging that can identify women with accelerated biological ovarian ageing. Potential strategies for improving ovarian response include the use of luteinizing hormone (LH) and growth hormone (GH). When endogenous LH levels are heavily suppressed by gonadotrophin-releasing hormone analogues, LH supplementation may help to optimize treatment outcomes for women with biologically older ovaries. Exogenous GH may improve oocyte development and counteract the age-related decline of oocyte quality. The effects of GH may be mediated by insulin-like growth factor-I, which works synergistically with follicle-stimulating hormone on granulosa and theca cells.

Conclusion: Patients with biologically older ovaries may benefit from a tailored approach based on individual patient characteristics. Among the most promising adjuvant therapies for improving ART outcomes in women of advanced reproductive age are the administration of exogenous LH or GH.

Background

Over recent years, the average age of patients seeking infertility treatment has increased [1]. Since the development of effective contraception in the 1960s, women have been able to delay childbearing [2,3], and the average maternal age increased by approximately 5 years between the periods 1965-1969 and 1995-1999 [3]. The tendency towards deferred childbirth has also risen steadily since assisted reproductive technology (ART) treatments for infertility became available in 1980 [4,5] (Fig. 1).

After approximately 30 years of age, fertility decreases with increasing age, with a slow but steady decline in fertility in women aged between 30 and 35 years, which is followed by an accelerated decline [6,7]. Data from the 16th to the early 19th century show that women who married late were more likely to die childless; women who married when more than 35 years of age had twice the chance of dying childless compared with those who married when aged 30-34 years [8]. Thus, delayed childbearing reduces the chance of achieving a spontaneous pregnancy [6].

A combination of delayed childbearing and reduced natural fecundity with increasing age has resulted in a steady increase in the number and proportion of women aged ≥35 years who are seeking ART treatment [9]. Unfortunately, the outcomes of treatment with ART are also adversely affected by advanced patient age, and it is becoming increasingly important to optimize treatment outcomes for these older patients [10].




Figure 1
Mean age at first childbirth in European women between 1980 and 2005. Reproduced with permission from T. Sobotka (pers. commun.).

Although chronological age is the most important predictor of ovarian response to follicle-stimulating hormone (FSH), the rate of reproductive ageing varies considerably among individuals. Both environmental and genetic factors contribute to biological ovarian ageing. Thus, chronological and biological age are not always equivalent. We review here the principal developmental and endocrine mechanisms of ovarian ageing that underlie the variability between chronological and biological age. We will also discuss the effect of biological ovarian ageing on ART treatment outcomes and consider potential treatment strategies for those of advanced biological reproductive age.

Methods

Electronic literature searches were performed via PubMed using combinations of the following keywords to identify relevant articles: 'AFC', 'age', 'AMH', 'ART', 'assisted reproduction', 'environmental', 'folliculogenesis', 'FSH', 'genetic', gonadotrophin', 'GH', 'infertility', 'LH', 'oogenesis' and 'ovarian'. All types of articles published in the English language were permitted and were unlimited by date of publication. The resulting publications were examined for relevance to the scope of the review (namely genetic and environmental factors that may influence ovarian ageing, the effect of biological ovarian ageing on ART outcomes, and potential treatment strategies for women of advanced biological reproductive age) and supplemented with other key publications that were known to the authors.

Ovarian function: folliculogenesis and oogenesis

The different stages of folliculogenesis are illustrated in Fig. 2 [11]. At birth, the ovaries contain a stock of approximately 1-2 million oocytes that are arrested at the first meiotic prophase [12]. Oocytes at the first meiotic prophase undergo atresia or resume meiosis after activation by an ovulation-inducing luteinizing hormone (LH) surge to form the haploid gamete for fertilization. In fact, almost all (99.9%) of the oocytes present at birth undergo atresia via apoptotic mechanisms [13]. Indeed, the total number of viable oocytes present in the ovaries at the onset of puberty is a small fraction of that present at birth.

The life-cycle of preovulatory follicles can be broken down into three successive phases: initiation, which occurs from birth to old age and is independent of gonadotrophic support; FSH-dependent progression, which requires tonic stimulation by FSH; and LH-responsive maturation, which occurs when FSH-induced genes fall under LH control, leading to oestrogen secretion and ovulation [14,15]. These processes ensure that the 'right' number of follicles are available at the 'right' stage of development, at the 'right' time in the menstrual cycle.




Figure 2
Life history of ovarian follicles endowment and maintenance, initial recruitment, maturation, atresia or cyclic recruitment, ovulation, and exhaustion. Reproduced with permission from McGee and Hsueh. Initial and cyclic recruitment of ovarian follicles. *Endocr Rev* 2000, **21**:200-214. © 2000. The Endocrine Society.

Early stages

Early stages of follicular growth are characterized by oocyte enlargement, granulosa cell proliferation (forming multiple layers around the oocyte) and development of the theca interna. From early infancy onwards, the proportion of the total number of healthy primordial follicles that proceeds to further development remains constant throughout a woman's reproductive life. Therefore, as the number of oocytes present in the ovaries decreases, the absolute number of developing follicles progressively declines with age [16].

The mechanisms responsible for initiating follicular growth are independent of gonadotrophins and may originate in the oocyte itself [17]. When a primordial follicle grows, the oocyte increases in size and the flattened cells surrounding it become cuboidal and proliferate to form the granulosa cell layer; the structure is then called a 'primary' follicle. All primary follicles that develop before puberty are destined to undergo atresia because the gonadotrophin support needed to promote full preovulatory growth is absent until shortly after this event [18]. Granulosa cells in healthy primary follicles continue to divide to

produce two or more layers while the zona pellucida forms around the enlarging oocyte. Outside the basement membrane, a layer of cells differentiates from the stroma and becomes the theca interna. The structure is now called a preantral follicle.

Intermediate stages

When approximately three layers of granulosa cells have formed in preantral follicles, fluid-filled spaces appear between the granulosa cells and gradually become confluent to form a single large antrum. Antrum formation is gonadotrophin-dependent. In humans, this growth stage lasts until follicles are approximately 2-4 mm in diameter. Healthy antral follicles are on the brink of entering the terminal stages of preovulatory development. However, to do so, they require appropriate, cyclical gonadotrophin stimulation. Thus, all antral follicles that develop before puberty will become atretic.

Ovulation

Usually one preovulatory follicle develops during each menstrual cycle, increasing in diameter from approximately 5 mm at the beginning of the cycle to more than

20 mm at ovulation 2 weeks later. During its last 6 days or so of development, a follicle increasingly secretes oestrogen and inhibin (INH), the classic biomarkers of preovulatory follicular development. These hormones lead to discharge of the mid-cycle LH surge from the pituitary gland, which in turn triggers resumption of oocyte meiotic maturation and ovulation.

The mechanisms of ovarian ageing

Follicular loss and the menopause

As a woman ages, her fecundity declines because of the loss of follicles from the ovary [19] and an associated reduction in oocyte quality [20]. The reduction in oocyte quality is in line with the increased incidence of miscarriages and chromosomal aberrations that occur after the age of 35 years [21]. The number of follicles in the human ovary declines at a rate that is bi-exponential. The rate of follicle loss more than doubles when the numbers fall below the critical level of 25,000; which occurs at approximately 37.5 years of age [22].

It has been suggested that a threshold number of follicles is required to maintain a regular menstrual cycle [23]. The peri-menopausal period is characterized by increasing irregularity in cycle length. The transition from peri-menopause to menopause is complete when approximately 1000 follicles remain in the ovaries; this occurs at an average age of 51 years. The time taken to reach this point from the critical threshold of 25,000 follicles seems to be fairly constant, at approximately 13 years [24].

Several years before menstrual cycles cease, initiation of follicular growth begins to accelerate, speeding up the loss of the residual follicular stock [25]; this occurs at approximately 35 years of age. This effect is associated with a gradual increase in circulating levels of FSH.

The central role of FSH in termination of folliculogenesis

FSH orchestrates the termination of folliculogenesis in human ovaries. The increase in circulating plasma FSH levels appears to be due mainly to reduced secretion of follicular growth and differentiation factors related to transforming growth factor- β that negatively affect the release of FSH from the pituitary gland.

INH and anti-Müllerian hormone (AMH) are produced by immature ovarian follicles and help to regulate secretion of FSH by the pituitary gland [26,27]. As the number of immature follicles declines with age, negative feedback control on FSH secretion is relaxed, and basal circulating levels of FSH rise. High levels of FSH promote inappropriate maturation of the granulosa cells of the residual preantral (INH B-secreting) follicles containing ova that have not completed their gonadotrophin-independent growth phase. These follicles eventually become atretic, presumably because of the asynchronous maturation of their ger-

minal and somatic components. The process is amplified as FSH levels continue to rise, until oestradiol and INH A levels also fall in the late peri-menopause, and menstrual cycles cease. The high FSH levels are also believed to underpin the gradual shortening of the follicular phase of the menstrual cycle with age, and the increased incidence of dizygotic twins [28].

Variability in reproductive ageing

Variability in ovarian ageing

The size of the initial oocyte stock, the proportion that undergoes atresia and the rate of initiation of growth of follicles are genetically determined variables [16,29]. Thus, the age at which the menopause occurs varies among individuals, and is determined mainly by genetic factors.

The peri-menopausal period, from the onset of cycle irregularity to menopause, is reported to be approximately 6 years, regardless of the age at menopause [30]. Similarly, the onset of subfertility for each individual woman is believed to begin at a relatively fixed interval prior to the menopause. This is corroborated by data from ART studies: women who respond poorly to ovarian stimulation tend to reach the menopause earlier [31-34]. Women who respond poorly to ovarian stimulation may be at a stage between the accelerated decline and complete loss of fertility.

Epidemiological studies show that 10% of women in the general population are menopausal by the age of 45 years [35,36]. Assuming a time interval of 13 years between the accelerated decline of ovarian follicles and complete loss of fertility, a woman who reaches the menopause at the age of 45 years may have begun a decline in follicle quantity and quality at approximately 32 years of age (although the maintenance of regular menstrual cycles would make her unaware of this possibility). Therefore, 10% of women may be at risk of unexplained reduced fecundity during their third decade. These women may have a poor response to ovarian stimulation, and could be described as having early 'biological ovarian ageing'.

Variability in ageing reflected by levels of gonadotrophins

FSH levels begin to increase long before the onset of menstrual cycle irregularity, and continue to rise thereafter [37,38]. Levels of both FSH and LH rise steadily during the period of follicle depletion during the peri-menopausal period, but the detailed dynamics involved are incompletely understood. The serum LH concentration usually starts to increase after the rise in FSH concentration, but in some cases this effect is not observed at all [39-41].

Ferrell et al. conducted a 5-year prospective study in order to investigate age-related changes in LH and FSH, in a group of 156 women within an age range of 25-58 years

at the beginning of the study [42]. The participants provided daily urine samples for 6 months per year in five consecutive years. These samples were analysed for aggregate distributions with age, individual trajectories with age, and variance in age-specific estimates within and between women.

The study confirmed that both FSH and LH levels increase with age, but the timing and magnitude of these changes were different for each hormone and varied among individuals. Both FSH and LH increased dramatically during the later peri-menopausal stages. FSH levels increased from normal to high within a relatively short time frame in the peri-menopausal years (<5 years). Although the most rapid increase in aggregate and individual FSH levels occurred after the age of 45, an increasing level of FSH was observed even in young women. However, any aggregate estimates of FSH or LH levels may be misleading as they represent a mixture of different trends seen in individuals, who have widely varying levels at different ages, and the rate of increase also differs among individuals. Figure 3 illustrates that the serum FSH rise started at different FSH concentrations for each woman. Thus, the findings of Ferrell et al. [42] illustrate the variable rate of ovarian ageing among individuals reflected in gonadotrophin levels. Moreover, independent of chronological age, ovarian ageing affects both oocyte fecundity and quality [43] and can negatively impact on the outcome of ART.

Factors that influence the rate of ovarian ageing

Both genetic and environmental factors influence the rate of ovarian ageing and ovarian sensitivity to gonadotrophins.




Figure 3
Some women undergo premature menopause whereas others conceive naturally in their late forties. Reproduced with permission from Ferrell et al. Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in luteinizing hormone and follicle-stimulating hormone with age. *Menopause* 2007, **14**:29-37.

Genetic influences on biological ovarian age and sensitivity to gonadotrophins

It is well established that genetic variations may affect ovarian response to gonadotrophins and ovarian ageing and even premature menopause. For instance, fragile X-associated primary ovarian insufficiency affects a proportion of female carriers of a mutated version of the *FMR1* gene [44]. It has been suggested that certain single nucleotide polymorphisms also affect sensitivity to gonadotrophins and ovarian ageing [45].

An extreme example of the relevance of a genetic cause of reduced ovarian gonadotrophin sensitivity to accelerated biological ageing is provided by the FSH-receptor haploinsufficient knock-out mouse (FSH-R+/-); these animals consequently have ovarian insensitivity due to a reduced number of FSH receptors [46]. FSH-R+/- mice reach reproductive maturity earlier but have smaller litter sizes than their wild-type counterparts [47]. There is no difference in the total number of follicles in the ovaries of 3-month-old FSH-R+/- versus wild-type mice. However, the ovaries of 7-month-old FSH-R+/- mice contain significantly fewer oocytes than wild-type controls, and serum gonadotrophins are higher [47].

Additionally, it has been demonstrated that oocytes obtained from older women may have inadequate reserves of energy due to age-related accumulated effects on their mitochondrial DNA [48]. Such a deficit results in mitochondrial dysfunction and a potential increase in the frequency of non-dysfunction, abnormalities in chromatid separation. These events probably contribute to the age-related increase in oocyte aneuploidy and the subsequent raised risk of having a foetus with a chromosome abnormality [49,50]. Another study suggests that chaotic mosaicism in human pre-implantation embryos is correlated with a low mitochondrial membrane potential, and this mechanism programs the developmental fate of embryos [51].

The importance of genetic characteristics in determining ovarian cycle and ovarian morphology with respect to the FSH receptor has also been described [52]. Women with the FSH receptor Ser⁶⁸⁰/Ser⁶⁸⁰ genotype, comprising approximately 20% of the female population, showed a significant increase in total menstrual cycle length and time from luteolysis to ovulation compared with control subjects (Asn⁶⁸⁰/Asn⁶⁸⁰ wild-type receptor). In addition, despite being normo-ovulatory, women with the Ser⁶⁸⁰ polymorphism displayed a significantly higher serum FSH level compared with the control population [52]. Consequently, this genotype is associated with a higher ovarian threshold to FSH and women with the Ser⁶⁸⁰ polymorphism have been reported to have a lower ovarian response to FSH stimulation during ART [53].

Although much research into ovarian resistance to gonadotrophins and ovarian ageing has focused on the gonadotrophin receptors, it is also important to consider the gonadotrophins themselves and other systems. A common variant of the LH gene (Trp⁸Arg and Ile¹⁵Thr of the beta subunit) encodes a protein with altered *in vitro* and *in vivo* activity [54], which thus may be less effective at supporting FSH-stimulated multi-follicular growth, resulting in a suboptimal ovarian response to standard stimulation regimens and in higher drug consumption [55]. An increased prevalence of the LH gene, beta subunit variant has been reported in Japanese patients with premature ovarian failure [56] and in Japanese infertility patients [57]. Therefore, women with this gene variant could benefit from exogenous LH supplementation during ovarian stimulation.

A possible link between ovarian age and the tumour suppressor gene, phosphatase and tensin homologue (PTEN) has been suggested. In a PTEN knock-out mouse model, all primordial ovarian follicles were activated prematurely [58]. In addition, although the low-density lipoprotein receptor-related protein 5 (*LRP5*) gene is considered to be primarily associated with bone metabolism via Wnt signalling, gene polymorphisms have been associated with a marked variation in circulating FSH levels in normal post-menopausal women [59].

Environmental influences on fecundity, biological ovarian age and sensitivity to gonadotrophins

Data from three epidemiological studies on the effect of biological and behavioural determinants of fertility in Bangladesh during 1975-1989 [60], 1981-1991 [61] and 1993-1994 [62] have shown that when women were stratified according to age there was a progressive decrease in fecundity rate, even among younger patients. Two studies reported that there was a significant effect of female education, female employment [61] and access to media (radio) on contraceptive use and a subsequent decline in fertility as women became more aware of family planning methods and viewed contraception more positively [62]. Lactational infecundity was also reported as a significant fertility-reducing factor in this population, although this factor was judged to remain constant while the fertility-reducing effect of contraception was predicted to increase [60].

Environmental factors may shorten the functional lifespan of a woman's ovaries. Diet may play a role in the occurrence of early menopause [63]. Cigarette smoking is one of the most common and important factors that has been found to reduce ovarian reserve [64]. Compounds in tobacco exert a deleterious effect on follicle maturation [65] and enhance follicle damage and premature ovarian failure [66]. The ovaries are extremely sensitive to aggressive chemotherapy or radiotherapy regimens for the treat-

ment of cancer [67] and women receiving alkylating agents such as cyclophosphamide and chlorambucil are at particularly high risk of gonadal dysfunction [68]. Although the precise mechanisms involved are incompletely understood, ovarian histology studies have shown that follicle stores are depleted and ovarian atrophy occurs after chemotherapy or radiotherapy treatment [67,69-72].

The effect of co-existing pathology on ovarian sensitivity to gonadotrophins

There is an association between endometriosis and infertility (30-50% of patients with endometriosis are infertile) but the visible endometriotic lesions contribute only a small proportion of the reduced fecundity of these women [73]. Data suggest that the adverse effects of endometriosis are not only related to abnormalities of reproductive anatomy but rather act to impair oocyte development [74]. A meta-analysis of data from two randomized trials showed that laparoscopic excision or ablation of lesions may improve the fertility of women with mild or moderate endometriosis [75].

There is also evidence of reduced responsiveness to gonadotrophins following laparoscopic ovarian cystectomy [76], suggesting that surgical treatment of endometriosis may further decrease a woman's ovarian reserve. Thus, it has been suggested that ovarian surgery should be undertaken only for the treatment of large endometriotic cysts or to treat pain that is refractory to medical treatment or exclude malignancy [77].

Impact of chronological versus biological age on ART treatment outcomes

Although ART treatments are now available for patients experiencing fertility problems, the likelihood of successful outcomes decreases with increasing female age. Poor ovarian response to stimulation is more common in women aged ≥ 35 years as the ovaries become less sensitive to FSH with increasing age [78]. The probability of embryo implantation and successful live birth after *in vitro* fertilization (IVF) also declines progressively in women over the age of 35 years [79,80] (Fig. 4). However, the outcome for patients using donor eggs remains relatively constant with increasing age, demonstrating that poor outcomes in older women relate to oocyte rather than to uterine factors [81].

Thus, biological ovarian age may be more important for the prognosis of fertility treatment than chronological ovarian age [43]. As a greater proportion of older patients present for ART, it will become increasingly important to critically assess their prognosis in order to counsel them appropriately and optimize treatment strategies. The use of biomarkers and genetic markers may allow estimation of the biological ovarian age of individual patients. This

information could assist greatly in informing patients and optimizing their management.

Biological ovarian age and ovarian response

As previously described, the menopause marks the depletion of follicles to below a critical threshold of approximately 1000, and the age at which menopause occurs is highly variable [24]. Biological ovarian age, as assessed by ovarian response to FSH during ART, can be used to predict the time to menopause (Fig. 5). A retrospective cohort study showed that a low residual number of oocytes, as reflected by a low number of oocytes (0-3) retrieved at first IVF treatment, is an important predictor of the risk of an early menopausal transition [82]. Ovarian response to gonadotrophins may, therefore, be important for appropriate counselling and management of patients undergoing ART.

Biological ovarian age and pregnancy rates

Biological ovarian age as assessed by FSH levels is an important prognostic factor for IVF-related pregnancy rates (Fig. 6). Studies have shown that elevated basal FSH levels are associated with a poor response to ovarian stimulation, which may be due to reduced oocyte numbers and can lead to lower ART pregnancy rates [83-86]. Akande et al. studied the ability of fertilized oocytes to implant successfully in relation to ovarian age as indicated by basal FSH levels. The authors reported that ovarian ageing affects both oocyte fecundity and quality, and can occur independently of chronological age [43].

ART management strategies for patients with biological ovarian ageing

Despite major advances in medical technology, there is currently no ART treatment strategy that can fully com-




Figure 4
Pregnancy and live birth rates following ART decline with increasing age. Based on SART data.




Figure 5
Poor response is indicative of older biological age. In vitro fertilization poor response to follicle-stimulating hormone is associated with earlier age of menopause. de Boer et al. Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. *Hum Reprod* 2003, 18:1544-1552. Reproduced by permission of Oxford University Press.

pensate for the natural decline of fertility with increasing age [2]. For example, simply using a high dose (300 IU) of FSH during ART will not improve pregnancy rates among women with an expected poor response (antral follicle count [AFC] [2-5 mm] < 5) [87]. Various adjuvant therapies for improving ART outcomes in women of advanced reproductive age have been suggested, such as the administration of exogenous LH or growth hormone (GH). Several potentially useful biomarkers are also emerging that can identify women with accelerated biological ovarian ageing. Patients with biologically older ovaries may benefit from a tailored approach based on individual charac-




Figure 6
Reduction in the rate of live births per embryo transferred against both increasing chronological age and increasing basal FSH in a prior spontaneous menstrual cycle. Akande et al. Biological versus chronological ageing of oocytes, distinguishable by raised FSH levels in relation to the success of IVF treatment. *Hum Reprod* 2002;17:2003-2008. Reproduced by permission of Oxford University Press. FSH, follicle-stimulating hormone.

teristics to maximize the chances of the low numbers of healthy follicles developing successfully.

Assessment of biological age using biomarkers

Although the diagnostic accuracy and clinical value of currently available tests of ovarian reserve is modest [88], there has been much interest in the use of basal hormone levels (serum FSH, AMH, INH B) or the AFC prior to stimulation. The decreasing sensitivity of the ovaries to FSH with age is reflected by rising basal serum FSH levels, which provide a crude surrogate marker of biological ovarian age when paired with the chronological age.

The AFC represents a better marker than either chronological age or basal FSH for assessing the ovarian biological age, and may be used to select older patients who have a good prognosis for IVF [89]. Older patients undergoing ovarian stimulation for IVF generally have lower AFCs than younger patients. A high AFC gives an older patient a better prognosis for IVF treatment outcome [90-92]. However, different genetic characteristics with respect to the FSH receptor may mean that using AFC as a sole assessment of IVF prognosis may be confounded in some women. Women with the FSH receptor Ser⁶⁸⁰/Ser⁶⁸⁰ genotype show a significantly greater increase in AFC during the early follicular phase compared with the Asn⁶⁸⁰/Asn⁶⁸⁰ (wild-type) genotype, and Ser⁶⁸⁰/Ser⁶⁸⁰ genotypes demonstrate ovarian resistance to FSH [52].

Because of their production by immature ovarian follicles, AMH and INH are also promising biomarkers of ovarian ageing [93,94]. Early follicular phase serum AMH levels correlate with the number of antral follicles [94-96] and oocytes retrieved [97,98] and live birth after ovarian stimulation [99]. AMH levels also decline progressively during the 5 years prior to the menopause [100].

Baseline AMH levels have been used successfully to individualize ovarian stimulation [101]. A recent study demonstrated that using a mixed treatment strategy of gonadotrophin-releasing hormone (GnRH) long agonist or antagonist protocols (rather than simply adjusting the FSH dose) resulted in good clinical pregnancy rates [101]. Importantly, it was shown that the use of a GnRH antagonist regimen for women with reduced circulating AMH levels (1-4.9 pmol/l) was associated with a trend towards increased clinical pregnancy rates, and reduced cycle cancellations and treatment burden compared with other study populations [101].

LH supplementation

The 'two cell - two gonadotrophin' model highlighted the role of LH in androgen production and release throughout folliculogenesis, and founded the concept that granulosa and theca cells are distinct follicular compartments

regulated by FSH and LH, respectively [15,102]. This classic model has since been revised to take account of the induction of granulosa cell LH receptor expression by FSH during advanced stages of antral follicular development [15,103-105]. Thus, LH regulates and integrates both granulosa and theca cell function during late preovulatory development.

FSH and LH cooperate to induce the local production of growth factors, which are required for the paracrine regulation of follicular maturation (although LH supersedes FSH to sustain granulosa cell function during intermediate-late stages of folliculogenesis) [106,107]. It has been proposed that a lack of either gonadotrophin may be counteracted by higher levels of the other. Indeed, FSH activity can be totally substituted by LH once granulosa cells express adequate numbers of LH receptors [104,108]. Conversely, increasing the dose of exogenous FSH during controlled ovarian stimulation can overcome GnRH-agonist mediated reduction of LH in many women.

This hypothesis explains why a low LH concentration or activity (below a subcritical threshold) may lead to impaired granulosa paracrine signalling and a correspondingly higher requirement for FSH. Furthermore, this theory gave rise to a suggestion that women with ovarian resistance to exogenous FSH, such as those with biologically older ovaries, may benefit from LH supplementation. Although some studies have failed to show an effect of LH supplementation in older women (≥ 35 years [109,110] or ≥ 40 years [111]), evidence of a beneficial effect of LH supplementation is gradually accumulating.

In a prospective randomized study using a long GnRH down-regulation protocol, significantly lower implantation and pregnancy rates were observed in women aged ≥ 35 years than in those aged < 35 years when only recombinant human (r-h)FSH was used for ovarian stimulation ($P < 0.03$ and $P < 0.05$, respectively); however, no age-related differences were found in women who received supplementation with r-hLH [112]. Moreover, the implantation rate among women aged ≥ 35 years who received r-hLH was significantly higher than in those who did not ($P < 0.05$) [112]. Similarly, the clinical pregnancy rate among patients aged ≥ 35 years at their first ART cycle was significantly higher if they received r-hLH than if they did not [113].

In a randomized controlled trial (using a GnRH antagonist), LH supplementation was associated with a significant improvement in implantation rates in women aged 36-39 years than stimulation with only FSH (26.7% vs 18.9%; $P = 0.03$), but this effect was not observed in younger patients [114]. Another positive effect of LH sup-

plementation was reported in a study of women aged >37 years at risk of a poor ovarian response (FSH > 7.6 IU/l) who received a flexible GnRH antagonist protocol with r-hLH supplementation, which resulted in a significantly greater number of mature oocytes than did a standard GnRH agonist short protocol [115].

Recent studies have attempted to define specific patient populations that would benefit most from LH supplementation. The greatest benefit of LH in ART has been seen in women with reduced responsiveness to gonadotrophin stimulation [116-121], which, it could be hypothesized, are those with biologically older ovaries. These early data are supported by a Cochrane systematic review in which a significantly higher pooled estimate of ongoing pregnancy was demonstrated in a sub-analysis of data from poor responders who received r-hLH supplementation [116].

LH could improve treatment outcomes following ART without affecting oocyte numbers, for example via beneficial effects of LH on oocytes via indirect routes such as cumulus cells [122]. Cumulus cells play a vital role in the maturation of oocytes during folliculogenesis. The direct action of LH may protect cumulus cells from apoptosis, so that they can continue to support the developing oocyte until ovulation, and ensure that the oocyte can sustain fertilization and early phases of embryogenesis [122].

Given the conflicting evidence and debate, more randomized-controlled trials are required to fully explore the potential utility of LH supplementation in IVF protocols.

GH supplementation

mRNA transcripts for the GH receptor are expressed in human oocytes and throughout pre-implantation embryonic development [123,124]. Indeed, human GH (hGH) receptors are present in cumulus cells, and both immature germinal vesicle (GV) and mature metaphase II stage oocytes [124]. Low concentrations of hGH in follicular fluid are associated with total fertilization failure, cleavage failure and poor embryo morphology [125].

It is likely that GH plays a role in the final stages of human oocyte maturation and early embryogenesis as it does for several other mammalian species [124]. hGH stimulates cytoplasmic maturation and may have a positive role in increasing total cell number in the embryo and in decreasing apoptosis [126], as described in bovine species [127]. In addition, GH is reported to upregulate the synthesis of insulin-like growth factor (IGF)-I, which acts to amplify the effects of FSH on granulosa and theca cells [128].

These observations suggested a possible role for hGH in *in vitro* oocyte maturation during ART. Early studies have confirmed that the addition of hGH to culture medium

improves *in vitro* maturation of immature GV oocytes [129,130]. Thus, the *in vitro* use of hGH may offer an opportunity to rescue cycles in which a high proportion of immature oocytes are retrieved [130].

The use of hGH in the management of female subfertility was first reported in the early 1990s [131,132] and since then its clinical use has been controversial. Although there are substantial *in vitro* data showing the critical importance of the IGF-IGFBP family (IGF-I, IGF-II and their binding proteins) to follicular development [133,134], subsequent studies failed to demonstrate a therapeutic advantage [135-141].

Interestingly, recent studies have shown more promising results. In a randomized trial of 100 women aged >40 years, co-stimulation with hGH (8 IU daily) led to significantly higher plasma and intrafollicular oestradiol levels, and clinical pregnancy and live birth rates, than did a standard ovarian stimulation protocol [142]. These data suggest that hGH may improve the potential for oocyte development and counteract the age-related decline of oocyte quality [142]. Kucuk et al. reported a significant increase in the number of oocytes recovered in poor responders receiving GH co-treatment with a GnRH agonist long protocol [128]. A recent systematic review and meta-analysis on the use of hGH in poor responders to ovarian stimulation concluded that there is some evidence to support a beneficial effect of GH on pregnancy rates [143]. Four placebo-controlled studies of poor responders were identified [131,136,139,144] and data from 82 patients were pooled. The addition of GH to ovarian stimulation protocols was shown to significantly increase live birth rates (odds ratio 5.22, 95% confidence interval 1.09-24.99; $P = 0.04$).

Conclusion

Biological ovarian age is more important than chronological age in predicting the outcome of ART. An increasing number of older patients are now presenting for ART treatment, and efforts should be made to critically assess each patient's biological ovarian age in order to counsel them appropriately regarding prognosis, and optimize individual treatment. When endogenous LH levels are heavily suppressed by GnRH analogues, LH supplementation may help to optimize treatment outcomes for women with biologically older ovaries. The potential genetic influences on ovarian gonadotrophin sensitivity discussed here are intriguing, and have encouraged an approach based on systems biology to further improve our understanding of gonadal function and ageing. Such translational medical research could refine the use of current therapies, producing valuable predictive models to guide use of current treatments, and may ultimately lead to a range of new therapies.

Competing interests

CA, SH and PH have declared no conflicts of interest. CMH is an employee of Merck Serono S.A. - Geneva, Switzerland (an affiliate of Merck KGaA, Darmstadt, Germany). DT was an employee of EMD Serono, Inc., Rockland, MA, USA (an affiliate of Merck KGaA, Darmstadt, Germany) when the manuscript was in development.

Authors' contributions

All authors were involved with the design, writing and reviewing of this manuscript and have approved the final version for submission.

Acknowledgements

The authors take full responsibility for the content of this review and wish to thank Julian M Jenkins for his contribution during his time with Merck Serono S.A. - Geneva. The authors also thank Hannah Wills and Joanna Brown of Caudex Medical (supported by Merck Serono S.A. - Geneva, Switzerland [an affiliate of Merck KGaA, Darmstadt, Germany]) for their assistance in the preparation of the manuscript.

References

- Balash J: **Investigation of the infertile couple: investigation of the infertile couple in the era of assisted reproductive technology: a time for reappraisal.** *Hum Reprod* 2000, **15**:2251-2257.
- Leridon H: **Can assisted reproduction technology compensate for the natural decline in fertility with age? A model assessment.** *Hum Reprod* 2004, **19**:1548-1553.
- te Velde ER, Pearson PL: **The variability of female reproductive ageing.** *Hum Reprod Update* 2002, **8**:141-154.
- Stephens PC, Edwards RG: **Birth after the reimplantation of a human embryo.** *Lancet* 1978, **2**:366.
- Stephens PC, Edwards RG, Walters DE: **Observations on 767 clinical pregnancies and 500 births after human in-vitro fertilization.** *Hum Reprod* 1986, **1**:89-94.
- Menken J, Trussell J, Larsen U: **Age and infertility.** *Science* 1986, **233**:1389-1394.
- ESHRE Capri Workshop Group: **Fertility and ageing.** *Hum Reprod Update* 2005, **11**:261-276.
- Menken J, Larsen U: **Fertility rates and aging.** In *Aging, Reproduction and the Climacteric* Edited by: Mastronianni L, Paulsen A. New York: Plenum Press; 1986:147-166.
- A long term analysis of the HFEA Register data 1991-2006** [<http://www.hfea.gov.uk/en/1540.html>]
- Howles CM, Kim CH, Elder K: **Treatment strategies in assisted reproduction for women of advanced maternal age.** *Int Surg* 2006, **91**:S37-S54.
- McGee EA, Hsueh AJ: **Initial and cyclic recruitment of ovarian follicles.** *Endocr Rev* 2000, **21**:200-214.
- Lobo RA: **Early ovarian ageing: a hypothesis. What is early ovarian ageing?** *Hum Reprod* 2003, **18**:1762-1764.
- Perez GI, Robles R, Knudson CM, Flaws JA, Korsmeyer SJ, Tilly JL: **Prolongation of ovarian lifespan into advanced chronological age by Bax-deficiency.** *Nat Genet* 1999, **21**:200-203.
- Hillier SG: **Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis.** *Hum Reprod* 1994, **9**:188-191.
- Hillier SG, Whitelaw PF, Smyth CD: **Follicular oestrogen synthesis: the 'two-cell, two-gonadotrophin' model revisited.** *Mol Cell Endocrinol* 1994, **100**:51-54.
- Faddy MJ, Gosden RG: **A model conforming the decline in follicle numbers to the age of menopause in women.** *Hum Reprod* 1996, **11**:1484-1486.
- Eppig JJ, Chesnel F, Hirao Y, O'Brien MJ, Pendola FL, Watanabe S, Wigglesworth K: **Oocyte control of granulosa cell development: how and why.** *Hum Reprod* 1997, **12**:127-132.
- Hirshfield AN: **Comparison of granulosa cell proliferation in small follicles of hypophysectomized, prepubertal, and mature rats.** *Biol Reprod* 1985, **32**:979-987.
- Klein NA, Soules MR: **Endocrine changes of the perimenopause.** *Clin Obstet Gynecol* 1998, **41**:912-920.
- Navot D, Bergh PA, Williams MA, Garrisi GJ, Guzman I, Sandler B, Grunfeld L: **Poor oocyte quality rather than implantation failure as a cause of age-related decline in female fertility.** *Lancet* 1991, **337**:1375-1377.
- te Velde ER, Scheffer GJ, Dorland M, Broekmans FJ, Fauser BC: **Developmental and endocrine aspects of normal ovarian aging.** *Mol Cell Endocrinol* 1998, **145**:67-73.
- Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF: **Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause.** *Hum Reprod* 1992, **7**:1342-1346.
- Gosden RG, Faddy MJ: **Ovarian aging, follicular depletion, and steroidogenesis.** *Exp Gerontol* 1994, **29**:265-274.
- Nikolaou D, Templeton A: **Early ovarian ageing: a hypothesis. Detection and clinical relevance.** *Hum Reprod* 2003, **18**:1137-1139.
- Gougeon A, Ecochard R, Thalabard JC: **Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women.** *Biol Reprod* 1994, **50**:653-663.
- Gregory SJ, Kaiser UB: **Regulation of gonadotropins by inhibin and activin.** *Semin Reprod Med* 2004, **22**:253-267.
- Durlinger AL, Visser JA, Themmen AP: **Regulation of ovarian function: the role of anti-Mullerian hormone.** *Reproduction* 2002, **124**:601-609.
- Beemsterboer SN, Homburg R, Gorter NA, Schats R, Hompes PG, Lambalk CB: **The paradox of declining fertility but increasing twinning rates with advancing maternal age.** *Hum Reprod* 2006, **21**:1531-1532.
- Faddy MJ, Gosden RG, Edwards RG: **Ovarian follicle dynamics in mice: a comparative study of three inbred strains and an F1 hybrid.** *J Endocrinol* 1983, **96**:23-33.
- den Tonkelaar I, te Velde ER, Looman CW: **Menstrual cycle length preceding menopause in relation to age at menopause.** *Maturitas* 1998, **29**:115-123.
- Farhi J, Homburg R, Ferber A, Orvieto R, Ben RZ: **Non-response to ovarian stimulation in normogonadotrophic, normogonadal women: a clinical sign of impending onset of ovarian failure pre-empting the rise in basal follicle stimulating hormone levels.** *Hum Reprod* 1997, **12**:241-243.
- de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, Klip H, van Leeuwen FE: **A low number of retrieved oocytes at in vitro fertilization treatment is predictive of early menopause.** *Fertil Steril* 2002, **77**:978-985.
- Nikolaou D, Lavery S, Turner C, Margara R, Trew G: **Is there a link between an extremely poor response to ovarian hyperstimulation and early ovarian failure?** *Hum Reprod* 2002, **17**:1106-1111.
- Lawson R, El-Toukhy T, Kassab A, Taylor A, Braude P, Parsons J, Seed P: **Poor response to ovulation induction is a stronger predictor of early menopause than elevated basal FSH: a life table analysis.** *Hum Reprod* 2003, **18**:527-533.
- Treloar AE: **Menstrual cyclicity and the pre-menopause.** *Maturitas* 1981, **3**:249-264.
- van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde E: **Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors.** *Fertil Steril* 1997, **68**:95-102.
- Santoro N, Brown JR, Adel T, Skurnick JH: **Characterization of reproductive hormonal dynamics in the perimenopause.** *J Clin Endocrinol Metab* 1996, **81**:1495-1501.
- Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N: **Executive summary: Stages of Reproductive Aging Workshop (STRAW).** *Fertil Steril* 2001, **76**:874-878.
- Freeman EW, Sammel MD, Gracia CR, Kapoor S, Lin H, Liu L, Nelson DB: **Follicular phase hormone levels and menstrual bleeding status in the approach to menopause.** *Fertil Steril* 2005, **83**:383-392.
- Hall Moran V, Leathard HL, Coley J: **Urinary hormone levels during the natural menstrual cycle: the effect of age.** *J Endocrinol* 2001, **170**:157-164.

41. Piltonen T, Koivunen R, Ruokonen A, Tapanainen JS: **Ovarian age-related responsiveness to human chorionic gonadotropin.** *J Clin Endocrinol Metab* 2003, **88**:3327-3332.
42. Ferrell RJ, O'Connor KA, Holman DJ, Brindle E, Miller RC, Rodriguez G, Simon JA, Mansfield PK, Wood JW, Weinstein M: **Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in luteinizing hormone and follicle-stimulating hormone with age.** *Menopause* 2007, **14**:29-37.
43. Akande VA, Fleming CF, Hunt LP, Keay SD, Jenkins JM: **Biological versus chronological ageing of oocytes, distinguishable by raised FSH levels in relation to the success of IVF treatment.** *Hum Reprod* 2002, **17**:2003-2008.
44. Santoro N: **Mechanisms of premature ovarian failure.** *Ann Endocrinol (Paris)* 2003, **64**:87-92.
45. De Leener A, Montanelli L, Van Durme J, Chae H, Smits G, Vassart G, Costagliola S: **Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology.** *J Clin Endocrinol Metab* 2006, **91**:555-562.
46. Danilovich N, Javeshghani D, Xing W, Sairam MR: **Endocrine alterations and signaling changes associated with declining ovarian function and advanced biological aging in follicle-stimulating hormone receptor haploinsufficient mice.** *Biol Reprod* 2002, **67**:370-378.
47. Danilovich N, Sairam MR: **Haploinsufficiency of the follicle-stimulating hormone receptor accelerates oocyte loss inducing early reproductive senescence and biological aging in mice.** *Biol Reprod* 2002, **67**:361-369.
48. May-Panloup P, Chretien MF, Jacques C, Vasseur C, Malthiery Y, Reynier P: **Low oocyte mitochondrial DNA content in ovarian insufficiency.** *Hum Reprod* 2005, **20**:593-597.
49. Munne S, Alikani M, Tomkin G, Grifo J, Cohen J: **Embryo morphology, developmental rates, and maternal age are correlated with chromosome abnormalities.** *Fertil Steril* 1995, **64**:382-391.
50. Munne S, Chen S, Fischer J, Colls P, Zheng X, Stevens J, Escudero T, Oter M, Schoolcraft B, Simpson JL, Cohen J: **Preimplantation genetic diagnosis reduces pregnancy loss in women aged 35 years and older with a history of recurrent miscarriages.** *Fertil Steril* 2005, **84**:331-335.
51. Wilding M, De Placido G, De Matteo L, Marino M, Alviggi C, Dale B: **Chaotic mosaicism in human preimplantation embryos is correlated with a low mitochondrial membrane potential.** *Fertil Steril* 2003, **79**:340-346.
52. Greb RR, Grieshaber K, Gromoll J, Sonntag B, Nieschlag E, Kiesel L, Simoni M: **A common single nucleotide polymorphism in exon 10 of the human follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of the menstrual cycle.** *J Clin Endocrinol Metab* 2005, **90**:4866-4872.
53. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M: **Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype.** *J Clin Endocrinol Metab* 2000, **85**:3365-3369.
54. Haavisto AM, Pettersson K, Bergendahl M, Virkamaki A, Huhtaniemi I: **Occurrence and biological properties of a common genetic variant of luteinizing hormone.** *J Clin Endocrinol Metab* 1995, **80**:1257-1263.
55. Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, Coppola M, Ranieri A, D'Uva M, De Placido G: **Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism.** *Reprod Biomed Online* 2009, **18**:9-14.
56. Takahashi K, Ozaki T, Okada M, Kurioka H, Kanasaki H, Miyazaki K: **Increased prevalence of luteinizing hormone beta-subunit variant in patients with premature ovarian failure.** *Fertil Steril* 1999, **71**:96-101.
57. Takahashi K, Kurioka H, Ozaki T, Kanasaki H, Kohsaka M, Miyazaki K, Karino K: **Increased prevalence of luteinizing hormone beta-subunit variant in Japanese infertility patients.** *Hum Reprod* 1998, **13**:3338-3344.
58. Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, Du C, Tang W, Hamalainen T, Peng SL, Lan ZJ, Cooney AJ, Huhtaniemi I, Liu K: **Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool.** *Science* 2008, **319**:611-613.
59. Zofkova I, Hill M, Zajickova K: **Association of C/T polymorphism in the LRP5 gene with circulating follicle stimulating hormone in Caucasian postmenopausal women.** *Physiol Res* 2007, **56**:735-739.
60. Islam MN, Islam MM: **Biological and behavioural determinants of fertility in Bangladesh: 1975-1989.** *Asia Pac Popul J* 1993, **8**:3-18.
61. Rahman MM, Islam MN, Islam MM: **Users of traditional methods of contraception in Bangladesh: 1981-91.** *J Biosoc Sci* 1996, **28**:257-264.
62. Barkat-e-Khuda, Hossain MB: **Fertility decline in Bangladesh: toward an understanding of major causes.** *Health Transit Rev* 1996, **6(Suppl)**:155-167.
63. Baird DD, Tyllavsky FA, Anderson JJB: **Do vegetarians have earlier menopause?** *Am J Epidemiol* 1998, **1**:907-908.
64. Freour T, Masson D, Mirallie S, Jean M, Bach K, Dejoie T, Barriere P: **Active smoking compromises IVF outcome and affects ovarian reserve.** *Reprod Biomed Online* 2008, **16**:96-102.
65. Soares SR, Melo MA: **Cigarette smoking and reproductive function.** *Curr Opin Obstet Gynecol* 2008, **20**:281-291.
66. Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, Laine J, Sakai T, Korsmeyer SJ, Casper RF, Sherr DH, Tilly JL: **Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals.** *Nat Genet* 2001, **28**:355-360.
67. Meiorow D, Nugent D: **The effects of radiotherapy and chemotherapy on female reproduction.** *Hum Reprod Update* 2001, **7**:535-543.
68. Donnez J, Martinez-Madrid B, Jadoul P, Van Langendonck A, Demylle D, Dolmans MM: **Ovarian tissue cryopreservation and transplantation: a review.** *Hum Reprod Update* 2006, **12**:519-535.
69. Himmelstein-Braw R, Peters H, Faber M: **Morphological study of the ovaries of leukaemic children.** *Br J Cancer* 1978, **38**:82-87.
70. Chapman RM, Sutcliffe SB, Malpas JS: **Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function.** *JAMA* 1979, **242**:1877-1881.
71. Marcello MF, Nuciforo G, Romeo R, Di Dino G, Russo I, Russo A, Palumbo G, Schiliro G: **Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment.** *Cancer* 1990, **66**:2099-2104.
72. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM: **Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease.** *Hum Reprod* 1993, **8**:2080-2087.
73. Practice Committee of the American Society for Reproductive Medicine: **Endometriosis and infertility.** *Fertil Steril* 2006, **86**:S156-S160.
74. Speroff L, Fritz MA: *Clinical Gynecologic Endocrinology and Infertility* Lippincott Williams & Wilkins; 2004.
75. Jacobson TZ, Barlow DH, Koninckx PR, Olive D, Farquhar C: **Laparoscopic surgery for subfertility associated with endometriosis.** *Cochrane Database Syst Rev* 2002:CD001398.
76. Somigliana E, Vercellini P, Vigano P, Ragni G, Crosignani PG: **Should endometriomas be treated before IVF-ICSI cycles?** *Hum Reprod Update* 2006, **12**:57-64.
77. Garcia-Velasco JA, Somigliana E: **Management of endometriomas in women requiring IVF: to touch or not to touch.** *Hum Reprod* 2009, **24**:496-501.
78. Weissman A, Howles CM: **Treatment strategies in assisted reproduction for the low responder patient.** In *Textbook of Assisted Reproductive Techniques* 3rd edition. Edited by: Gardener E, Weissman A, Howles CM, Shoham Z. Informa Healthcare; 2008.
79. Templeton A, Morris JK, Parslow W: **Factors that affect outcome of in-vitro fertilisation treatment.** *Lancet* 1996, **348**:1402-1406.
80. van Kooij RJ, Looman CW, Habbema JD, Dorland M, te Velde ER: **Age-dependent decrease in embryo implantation rate after in vitro fertilization.** *Fertil Steril* 1996, **66**:769-775.
81. Abdalla HI, Burton G, Kirkland A, Johnson MR, Leonard T, Brooks AA, Studd JW: **Age, pregnancy and miscarriage: uterine versus ovarian factors.** *Hum Reprod* 1993, **8**:1512-1517.
82. de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, van Leeuwen FE: **Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment.** *Hum Reprod* 2003, **18**:1544-1552.
83. Sharif K, Elgendy M, Lashen H, Afnan M: **Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome.** *Br J Obstet Gynaecol* 1998, **105**:107-112.
84. Pruksananonda K, Boonkasemsanti W, Virutamasen P: **Basal follicle-stimulating hormone levels on day 3 of previous cycle are predictive of in vitro fertilization outcome.** *J Med Assoc Thai* 1996, **79**:365-369.

85. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z: **Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome.** *Fertil Steril* 1989, **51**:651-654.
86. Abdalla H, Thum MY: **An elevated basal FSH reflects a quantitative rather than qualitative decline of the ovarian reserve.** *Hum Reprod* 2004, **19**:893-898.
87. Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER: **Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial.** *Hum Reprod* 2005, **20**:611-615.
88. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB: **A systematic review of tests predicting ovarian reserve and IVF outcome.** *Hum Reprod Update* 2006, **12**:685-718.
89. Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER: **The antral follicle count is a better marker than basal follicle-stimulating hormone for the selection of older patients with acceptable pregnancy prospects after in vitro fertilization.** *Fertil Steril* 2005, **83**:811-814.
90. Nahum R, Shifren JL, Chang Y, Leykin L, Isaacson K, Toth TL: **Antral follicle assessment as a tool for predicting outcome in IVF--is it a better predictor than age and FSH?** *J Assist Reprod Genet* 2001, **18**:151-155.
91. Hansen KR, Morris JL, Thyer AC, Soules MR: **Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting.** *Fertil Steril* 2003, **80**:577-583.
92. Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, te Velde ER: **Impact of repeated antral follicle counts on the prediction of poor ovarian response in women undergoing in vitro fertilization.** *Fertil Steril* 2004, **81**:35-41.
93. Lawson R, El-Toukhy T, Kassab A, Taylor A, Braude P, Parsons J, Seed P: **Poor response to ovulation induction is a stronger predictor of early menopause than elevated basal FSH: a life table analysis.** *Hum Reprod* 2003, **18**:527-533.
94. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC: **Antimullerian hormone serum levels: a putative marker for ovarian aging.** *Fertil Steril* 2002, **77**:357-362.
95. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J: **Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3.** *Hum Reprod* 2003, **18**:323-327.
96. van Rooij I, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen AP: **Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve.** *Hum Reprod* 2002, **17**:3065-3071.
97. van Roijen JH, Ooms MP, Weber RF, Brinkmann AO, Grootegoed JA, Vreeburg JT: **Comparison of the response of rat testis and accessory sex organs to treatment with testosterone and the synthetic androgen methyltrienolone (R1881).** *J Androl* 1997, **18**:51-61.
98. Ficiocioglu C, Kutlu T, Baglam E, Bakacak Z: **Early follicular antimullerian hormone as an indicator of ovarian reserve.** *Fertil Steril* 2006, **85**:592-596.
99. Nelson SM, Yates RW, Fleming R: **Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy.** *Hum Reprod* 2007, **22**:2414-2421.
100. Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, Harlow S, Randolph JF Jr: **Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition.** *J Clin Endocrinol Metab* 2008, **93**:3478-3483.
101. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R: **Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception.** *Hum Reprod* 2009, **24**:867-875.
102. Fevold HL: **Synergism of follicle stimulating and luteinizing hormones in producing estrogen secretion.** *Endocrinology* 1941, **28**:33-36.
103. Erickson GF, Wang C, Hsueh AJ: **FSH induction of functional LH receptors in granulosa cells cultured in a chemically defined medium.** *Nature* 1979, **279**:336-338.
104. Filicori M, Cognigni GE, Pocognoli P, Ciampaglia W, Bernardi S: **Current concepts and novel applications of LH activity in ovarian stimulation.** *Trends Endocrinol Metab* 2003, **14**:267-273.
105. Shima K, Kitayama S, Nakano R: **Gonadotropin binding sites in human ovarian follicles and corpora lutea during the menstrual cycle.** *Obstet Gynecol* 1987, **69**:800-806.
106. Huang ZH, Clayton PE, Brady G, Morris ID: **Insulin-like growth factor-I gene expression in human granulosa-lutein cells.** *J Mol Endocrinol* 1994, **12**:283-291.
107. Zhou J, Bondy C: **Anatomy of the human ovarian insulin-like growth factor system.** *Biol Reprod* 1993, **48**:467-482.
108. Zeleznik AJ, Hillier SG: **The role of gonadotropins in the selection of the preovulatory follicle.** *Clin Obstet Gynecol* 1984, **27**:927-940.
109. Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J: **Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age.** *Fertil Steril* 2006, **85**:925-931.
110. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, Tarlatzis BC: **Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis.** *Hum Reprod Update* 2007, **13**:445-452.
111. Barrenetxea G, Agirregoikoa JA, Jimenez MR, Lopez de Larruzea A, Ganzabal T, Carbonero K: **Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.** *Fertil Steril* 2008, **89**:546-553.
112. Humaidan P, Bungum M, Bungum L, Yding Andersen C: **Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study.** *Reprod Biomed Online* 2004, **8**:635-643.
113. Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E: **Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment.** *Reprod Biomed Online* 2004, **8**:175-182.
114. Bosch E, Labarta E, Simón C, Remohi J, Pellicer A: **The impact of luteinizing hormone supplementation in gonadotropin releasing hormone antagonist cycles. An age adjusted randomized trial.** *Fertil Steril* 2008, **90**:S41.
115. De Placido G, Mollo A, Clarizia R, Strina I, Conforti S, Alviggi C: **Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.** *Fertil Steril* 2006, **85**:247-250.
116. Mochtar MH, van der Veen F, Ziech M, van Wely M: **Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles.** *Cochrane Database Syst Rev* 2007:CD005070.
117. Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N: **Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques.** *Fertil Steril* 2004, **82**:1521-1526.
118. De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, De Palo R, Ranieri A, Colacurci N, Mollo A: **Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.** *Hum Reprod* 2005, **20**:390-396.
119. Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A: **Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization.** *Fertil Steril* 2005, **83**:309-315.
120. De Placido G, Mollo A, Alviggi C, Strina I, Varricchio MT, Ranieri A, Colacurci N, Tolino A, Wilding M: **Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH.** *Hum Reprod* 2001, **16**:1875-1879.
121. De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, Wilding M, Varricchio MT, Borrelli AL, Conforti S: **Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH)**

- after pituitary downregulation. *Clin Endocrinol (Oxf)* 2004, **60**:637-643.
122. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC: **Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.** *Fertil Steril* 2007, **87**:542-546.
 123. Abir R, Garor R, Felz C, Nitke S, Krissi H, Fisch B: **Growth hormone and its receptor in human ovaries from fetuses and adults.** *Fertil Steril* 2008, **90**:1333-1339.
 124. Ménézio YJ, el Mouatassim S, Chavrier M, Servy EJ, Nicolet B: **Human oocytes and preimplantation embryos express mRNA for growth hormone receptor.** *Zygote* 2003, **11**:293-297.
 125. Mendoza C, Cremades N, Ruiz-Requena E, Martinez F, Ortega E, Bernabeu S, Tesarik J: **Relationship between fertilization results after intracytoplasmic sperm injection, and intrafollicular steroid, pituitary hormone and cytokine concentrations.** *Hum Reprod* 1999, **14**:628-635.
 126. Izadyar F, Van Tol HT, Hage VVG, Bevers MM: **Preimplantation bovine embryos express mRNA of growth hormone receptor and respond to growth hormone addition during in vitro development.** *Mol Reprod Dev* 2000, **57**:247-255.
 127. Kolle S, Stojkovic M, Boie G, Wolf E, Sinowatz F: **Growth hormone inhibits apoptosis in in vitro produced bovine embryos.** *Mol Reprod Dev* 2002, **61**:180-186.
 128. Kucuk T, Kozinoglu H, Kaba A: **Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial.** *J Assist Reprod Genet* 2008, **25**:123-127.
 129. Ménézio YJ, Nicollet B, Rollet J, Hazout A: **Pregnancy and delivery after in vitro maturation of naked ICSI-GV oocytes with GH and transfer of a frozen thawed blastocyst: case report.** *J Assist Reprod Genet* 2006, **23**:47-49.
 130. Ménézio YJ, Jacquet J, Girard A, Chouteau J, Nicollet B, Servy E: **In vitro maturation of human oocytes with growth hormone.** *Fertil Steril* 2003, **80**:277.
 131. Owen EJ, Shoham Z, Mason BA, Ostergaard H, Jacobs HS: **Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial.** *Fertil Steril* 1991, **56**:1104-1110.
 132. Shoham Z, Homburg R, Owen EJ, Conway GS, Ostergaard H, Jacobs HS: **The role of treatment with growth hormone in infertile patients.** *Baillieres Clin Obstet Gynaecol* 1992, **6**:267-281.
 133. Adashi EY, Resnick CE, Hurwitz A, Ricciarelli E, Hernandez ER, Roberts CT, Leroith D, Rosenfeld R: **Insulin-like growth factors: the ovarian connection.** *Hum Reprod* 1991, **6**:1213-1219.
 134. Adashi EY, Resnick CE, Hernandez ER, Hurwitz A, Roberts CT, Leroith D, Rosenfeld R: **Insulin-like growth factor I as an intra-ovarian regulator: basic and clinical implications.** *Ann N Y Acad Sci* 1991, **626**:161-168.
 135. Howles CM, Loumays E, Germond M, Yates R, Brinsden P, Healy D, Bonaventura LM, Strowitzki T: **Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization?** *Hum Reprod* 1999, **14**:1939-1943.
 136. Suikkari A, Maclachlan V, Koistinen R, Seppala M, Healy D: **Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology.** *Fertil Steril* 1996, **65**:800-805.
 137. Shaker AG, Fleming R, Jamieson ME, Yates RW, Coutts JR: **Absence of effect of adjuvant growth hormone therapy on follicular responses to exogenous gonadotropins in women: normal and poor responders.** *Fertil Steril* 1992, **58**:919-923.
 138. Hughes SM, Huang ZH, Morris ID, Matson PL, Buck P, Lieberman BA: **A double-blind cross-over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in-vitro fertilization.** *Hum Reprod* 1994, **9**:13-18.
 139. Dor J, Seidman DS, Amudai E, Bider D, Levran D, Mashiach S: **Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind study.** *Hum Reprod* 1995, **10**:40-43.
 140. Younis JS, Simon A, Koren R, Dorembus D, Schenker JG, Laufer N: **The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study.** *Fertil Steril* 1992, **58**:575-580.
 141. Kotarba D, Kotarba J, Hughes E: **Growth hormone for in vitro fertilization.** *Cochrane Database Syst Rev* 2000:CD000099.
 142. Tesarik J, Hazout A, Mendoza C: **Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone.** *Hum Reprod* 2005, **20**:2536-2541.
 143. Kyrrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC: **How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis.** *Fertil Steril* 2009, **91**:749-766.
 144. Zhuang GL, Wong SX, Zhou CQ: **The effect of co-administration of low dosage growth hormone and gonadotropin for ovarian hyperstimulation in vitro fertilization and embryo transfer.** *Zhonghua Fu Chan Ke Za Zhi* 1994, **29**:471-4, 510.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

